Pfizer Q1 revenue marginally falls
Net income attributable to the company was $2.22bn for the first quarter of 2011, compared to $2.02bn for the same period last year. For full-year 2011, Pfizer anticipated
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.